Translationaler Protein-Biomarker-Workshop

Translationaler Protein-Biomarker-Workshop

Titel: Translationaler Protein-Biomarker-Workshop

Termin: 17. und 18. September 2026

Ort: NMI, Markwiesenstraße 55, 72770 Reutlingen

Teilnahmebeitrag: 65 Euro


Translational Protein Biomarker Workshop, co-organized by NMI, the GBM Bioanalytics Study Group, and SIGNATOPE GmbH

The NMI is hosting a Protein Biomarker Workshop together with the GBM Bioanalytics Study Group and SIGNATOPE.

The event brings together leading international scientists from academic research, the pharmaceutical industry, and clinical practice. The focus is on current developments in protein biomarker research, particularly innovative technologies such as ultrasensitive immunoassays, multiplex affinity platforms, and mass spectrometric methods for quantitative protein analysis.

In addition to technological aspects, the conference will also address regulatory requirements and strategies for the successful translation of biomarkers into clinical trials. Application examples range from drug-induced organ damage and therapy monitoring to concepts in personalized medicine.

Presentations by:

Dr. Christoph Borchers (Jewish General Hospital, Montreal)

Warren Glaab (Merck Sharp & Dohme, USA)

Prof. Dr. Chris Goldring (University of Liverpool, UK)

Dr. med. Klemens Ruprecht (Universität Heidelberg)

Dr. Ulrich Kunz (Boehringer Ingelheim)

Dr. Dr. med. Susanne Roth (Universitätsklinikum Tübingen)

Prof. Dr. Jochen Schwenk (KTH Royal Institute of Technology, Stockholm)

Dr. Marcus Bantscheff (Roche, Basel)

register now

Our latest News

discover more
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]

Cells Have an Early-Warning System for Stress in Mitochondria

Cells Have an Early-Warning System for Stress in Mitochondria

Internal protective mechanism responds to the very first signs of mitochondrial dysfunction Mitochondria – the powerhouses of the cell – have their own monitoring system that detects oxidative stress at a very early stage. It activates protective mechanisms even before the damage caused by this stress can spread to the rest of the cell. This […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp